M464 inhibits activation of NLRP3 inflammasome and inflammatory response in mice
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-01 04:03
摘要：
M464 is a newly synthesized non-steroidal anti-inflammatory drug (NSAID) that releases hydrogen sulfide, demonstrating significant anti-inflammatory effects by inhibiting the NLRP3 inflammasome. In vitro and in vivo studies reveal its potential to protect against acute lung and liver injuries, suggesting it could serve as a promising therapeutic option for inflammatory diseases. The innovative mechanism of action and the results from animal models underscore M464's potential for early-stage investment in the biopharmaceutical sector.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
M464 effectively suppressed the activation of the NLRP3 inflammasome.
In vivo experiments demonstrated that M464 exhibited robust protective effects against NLRP3-driven acute lung injury and acute liver injury.
M464 shows potential as a novel lead compound for addressing NLRP3-related inflammatory diseases.
真实性检查
否
AI评分总结
M464 is a newly synthesized non-steroidal anti-inflammatory drug (NSAID) that releases hydrogen sulfide, demonstrating significant anti-inflammatory effects by inhibiting the NLRP3 inflammasome. In vitro and in vivo studies reveal its potential to protect against acute lung and liver injuries, suggesting it could serve as a promising therapeutic option for inflammatory diseases. The innovative mechanism of action and the results from animal models underscore M464's potential for early-stage investment in the biopharmaceutical sector.